BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 28981732)

  • 1. Diagnostic and Prognostic Value of IL-10, FABP2 and LPS Levels in HCC Patients.
    Morkunas E; Vaitkeviciute E; Varkalaite G; Pilvinis V; Skieceviciene J; Kupcinskas J
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhang QY; Ding W; Mo JS; Ou-Yang SM; Lin ZY; Peng KR; Liu GP; Lu JJ; Yue PB; Lei JP; Wang YD; Zhang XL
    Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38609562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte subsets and inflammatory factors as predictors of immunotherapy efficacy in patients with hepatocellular carcinoma.
    Shuyue G; Jiamin C; Niansong Q
    Sci Rep; 2023 Dec; 13(1):22480. PubMed ID: 38110467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
    Chamseddine S; Mohamed YI; Lee SS; Yao JC; Hu ZI; Tran Cao HS; Xiao L; Sun R; Morris JS; Hatia RI; Hassan M; Duda DG; Diab M; Mohamed A; Nassar A; Datar S; Amin HM; Kaseb AO
    Oncology; 2023; 101(11):730-737. PubMed ID: 37467732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
    Öcal O; Schütte K; Kupčinskas J; Morkunas E; Jurkeviciute G; de Toni EN; Ben Khaled N; Berg T; Malfertheiner P; Klümpen HJ; Sengel C; Basu B; Valle JW; Benckert J; Gasbarrini A; Palmer D; Seidensticker R; Wildgruber M; Sangro B; Pech M; Ricke J; Seidensticker M
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):475-485. PubMed ID: 33855585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
    Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
    Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
    Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
    BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
    Lu LC; Chen PJ; Yeh YC; Hsu CH; Chen HM; Lai MS; Shao YY; Cheng AL
    Anticancer Res; 2017 May; 37(5):2593-2599. PubMed ID: 28476832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
    Faloppi L; Scartozzi M; Bianconi M; Svegliati Baroni G; Toniutto P; Giampieri R; Del Prete M; De Minicis S; Bitetto D; Loretelli C; D'Anzeo M; Benedetti A; Cascinu S
    BMC Cancer; 2014 Feb; 14():110. PubMed ID: 24552144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.
    Shao YY; Lin H; Li YS; Lee YH; Chen HM; Cheng AL; Hsu CH
    Jpn J Clin Oncol; 2017 Oct; 47(10):949-953. PubMed ID: 28981732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
    Liu D; Liu A; Peng J; Hu Y; Feng X
    Eur J Med Res; 2015 Feb; 20(1):12. PubMed ID: 25649133
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.